Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting

ClinicalTrials.gov ID: NCT00642512

Public ClinicalTrials.gov record NCT00642512. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Efficacy Study of Oral Dronabinol Alone and in Combination With Ondansetron Versus Ondansetron Alone in Subjects With Delayed Chemotherapy-Induced Nausea and Vomiting

Study identification

NCT ID
NCT00642512
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Solvay Pharmaceuticals
Industry
Enrollment
64 participants

Conditions and interventions

Interventions

  • dronabinol Drug
  • ondansetron Drug
  • dronabinol/ondansetron Drug
  • placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2003
Primary completion
Jun 30, 2004
Completion
Jun 30, 2004
Last update posted
Apr 2, 2008

2003 – 2004

United States locations

U.S. sites
43
U.S. states
22
U.S. cities
40
Facility City State ZIP Site status
Site 970 Tucson Arizona
Site 950 Anaheim California
Site 925 Fountain Valley California
Site 913 Greenbrae California
Site 909 Los Angeles California
Site 908 Pomona California
Site 943 Rancho Mirage California
Site 932 Boynton Beach Florida
Site 924 Hollywood Florida
Site 940 Lakeland Florida
Site 921 New Port Richey Florida
Site 929 New Port Richey Florida
Site 933 Ormond Beach Florida
Site 922 Marietta Georgia
Site 928 Harvey Illinois
Site 914 Orland Park Illinois
Site 926 Skokie Illinois
Site 946 Springfield Illinois
Site 956 Terre Haute Indiana
Site 905 Southfield Michigan
Site 916 Fergus Falls Minnesota
Site 937 Greenwood Mississippi
Site 958 St Louis Missouri
Site 904 Missoula Montana
Site 919 Little Silver New Jersey
Site 920 Voorhees Township New Jersey
Site 948 Brooklyn New York
Site 953 Brooklyn New York
Site 910 The Bronx New York
Site 949 Valhalla New York
Site 947 Wilmington North Carolina
Site 902 Bismarck North Dakota
Site 942 Fargo North Dakota
Site 944 Columbus Ohio
Site 934 Oklahoma City Oklahoma
Site 931 Philadelphia Pennsylvania
Site 906 Pittsburgh Pennsylvania
Site 918 Charleston South Carolina
Site 923 North Charleston South Carolina
Site 917 Chattanooga Tennessee
Site 939 Chattanooga Tennessee
Site 915 Texarkana Texas
Site 951 Arlington Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00642512, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 2, 2008 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00642512 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →